articleTop 1% cited

SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12

Transplantation · 2000 · Vol. 69(7) · pp. 1252–1260

Henri Kreis✉(Hôpital Necker-Enfants Malades)Jean‐Marc Cisterne(Hôpital Rangueil)W. Land(München Klinik)Lars Wramner(Sahlgrenska University Hospital)Jean‐Paul Squifflet(Cliniques Universitaires Saint-Luc)Daniel Abramowicz(Erasmus Hospital)Josep M. Campistol(Hospital Clínic de Barcelona)Jos -Maria Morales(Research Institute Hospital 12 de Octubre)Jos -Maria Grinyo(Bellvitge University Hospital)Georges Mourad(European Society of Cardiology)Fran ois-Claude Berthoux(Hôpital Nord)Christina Brattstr m(Stockholm University College of Music Education)Yvon Lebranchu(Hôpital Bretonneau)P Vialtel(Sahlgrenska University Hospital)

View via DOI Publisher page

Abstract

Patient and graft survival and the incidence of biopsy-proven acute rejection at 12 months were comparable between sirolimus and CsA, whereas safety profiles were different. These data suggest that sirolimus may be used as primary therapy for the prevention of acute rejection.

Renal Transplantation Outcomes and Treatments Neurological Complications and Syndromes Pharmacological Effects and Toxicity StudiesSirolimusMedicineUrologyTransplantationAzathioprineTrough levelGastroenterologyRenal functionMycophenolic acidInternal medicine

MeSH terms

Acute DiseaseAdolescentAdultAgedChildDose-Response Relationship, DrugDrug Therapy, CombinationFemaleGraft RejectionHumansImmunosuppressive AgentsMaleMiddle AgedMycophenolic AcidTransplantation, Homologous

Citations

541

FWCI

29.91

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

END-STAGE RENAL DISEASE (ESRD) AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLTX) USING CALCINEURIN-BASED IMMUNOTHERAPY1